Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: Subanalysis of REVEAL and the open-label extension study
作者单位：Abbott Laboratories, Abbott Park, IL, United States[1]Probity Medical Research, Waterloo, ON, Canada[2]Centre Dermatologique du Québec Métropolitain, QC, Canada[3]Baylor Research Institute, Dallas, TX, United States[4]
换一批
